Comparing Bosutinib Versus Imatinib in Newly Diagnosed CML

June 6, 2017
Jorge Cortes, MD

Jorge Cortes, MD, deputy chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses initial results from the BFORE trial, which is exploring bosutinib (Bosulif) versus imatinib (Gleevec) for newly diagnosed chronic myeloid leukemia.